Oncorus Inc. (ONCR)
0.13
0.00 (0.00%)
At close: Dec 29, 2023, 7:55 PM
0.00% (1D)
| Bid | n/a |
| Market Cap | 0 |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -94.27M |
| EPS (ttm) | -3.48 |
| PE Ratio (ttm) | -0.03620689655172414 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 135,947 |
| Avg. Volume (20D) | 108,675 |
| Open | 0.13 |
| Previous Close | 0.13 |
| Day's Range | 0.13 - 0.20 |
| 52-Week Range | 0.01 - 0.47 |
| Beta | 1.95 |
About ONCR
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 2, 2020
Employees 64
Stock Exchange NASDAQ
Ticker Symbol ONCR
Website https://www.oncorus.com